SOLICITATION NOTICE
A -- In Vitro Metabolism & Metabolite Quantification
- Notice Date
- 2/23/2009
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6101 Executive Boulevard, Room 260 - MSC 8402, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- N01DA-09-8891InVitro
- Point of Contact
- Korriise L. LaRoche,, Phone: (301) 443-6677, Craig D Sager,, Phone: (301) 443-6677
- E-Mail Address
-
larochek@mail.nih.gov, cs591t@nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Institute on Drug Abuse (NIDA) is soliciting proposals from qualified organizations having the capability to provide in vitro metabolism and permeability determinations for its medications development program. The in vitro metabolism studies for this contract typically include metabolite profiling for interspecies comparison using hepatocytes and microsomes, CYP 450 phenotyping reaction, CYP 450 inhibition, and CYP 450 induction for potential medications. It may also include evaluation of in vitro metabolism by other systems such as hepatic cytosol, hepatic mitochondrial fraction, or Phase II reactions (glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione, conjugation with amino acids). This contract should also provide structure identification of major metabolites by mass spectrometry or nuclear magnetic resonance (NMR). Additional in vitro studies include determination of intestinal and or blood-brain barrier permeability of new compounds. The data obtained will be used by the NIDA and NIDA sponsored investigators for submissions to the Food and Drug Administration (FDA). The reports shall be adequate in format and substance for submission to the FDA in support of IND and NDA applications. Due to the nature of the compounds that will be evaluated under this contract, it is mandatory that offerors possess a DEA Registration for Chemical Analysis or Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess, or demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. NIDA anticipates a 3-year fixed price contract with options to extend the contract up to 2 years. RFP No. N01DA-9-8891 will be available electronically on or about March 13, 2009. You can access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Response to the RFP will be due on or about April 24, 2009. NIDA will consider proposals submitted by any responsible offer. Following proposal submission and the initial review, the Contracting Officer may require additional documentation from offerors in the competitive range. This advertisement does not commit the Government to award a contract. Note 26. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government’s requirement with a commercial item within 15 days of this notice.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=f2c51ae96c90f28e20c55827cacbee88&tab=core&_cview=1)
- Record
- SN01755163-W 20090225/090223214627-f2c51ae96c90f28e20c55827cacbee88 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |